News | April 03, 2012

PCI-Associated Renal Complications Increase Significantly Among Medicare Patients

Study warrants focus on contrast-induced nephropathy

April 3, 2012 — Incidences of renal complications, specifically acute renal failure (ARF) and new hemodialysis (HD), continue to increase significantly among Medicare beneficiaries (MB) admitted for percutaneous coronary intervention (PCI). This was according to a study presented last week at the American College of Cardiology’s (ACC) 61st Annual Scientific Session.

While patients admitted with impaired renal function are at increased risk, approximately 10 percent of elective patients will suffer renal complications without prior indicators. Researchers said the findings warrant more focus on implementation of a contrast-induced nephropathy (CIN) protocol to reduce complications.

The study, conducted Oct. 1, 2008 to Sept. 30, 2010, was designed to report two-year trends in PCI-associated renal failure. The study group included all Medicare patients admitted for a PCI without CABG (coronary artery bypass graft) surgery or valve surgery in an acute care hospital. The study population was divided into two sub-samples:

  • Elective PCI: Patients who did not have primary ST segment elevation myocardial infarction (STEMI) and did not arrive in cardiogenic shock or cardiac arrest.
  • Non-Elective PCI: All MBs not undergoing an elective PCI.

 

All patients studied experienced significant increases in both acute renal failure (ARF) and new hemodialysis (HD) year over year, by 29 percent and 21 percent, respectively. The percentage increase for both complications was slightly higher for those patients undergoing elective PCI, while the increase in ARF among patients undergoing non-elective PCI was nearly double that of elective patients.

“The rise in renal complications is concerning, given their close association with worse morbidity and mortality,” said April Simon, R.N., MSN, one of the researchers and president of Cardiac Data Solutions, which conduced the study. “This data suggests that increased focus on contrast-induced nephropathy prevention protocols may improve clinical outcomes. Any patient receiving contrast is at risk for CIN; insuring that the amount of contrast is minimized and paying particular attention to hydration are imperative.”

For more information: www.ereleases.com/pic/Cardiac-Data-Solutions.pdf.

Related Content

Philips Introduces Technology Maximizer Program for Imaging Equipment Upgrades
Technology | Imaging | January 17, 2018
January 17, 2018 — Philips recently announced the launch of Technology Maximizer, a cross-modality program designed t
Study Finds No Evidence that Gadolinium Causes Neurologic Harm

MR images through, A, C, E, basal ganglia and, B, D, F, posterior fossa at level of dentate nucleus. Images are shown for, A, B, control group patient 4, and the, C, D, first and, E, F, last examinations performed in contrast group patient 13. Regions of interest used in quantification of signal intensity are shown as dashed lines for globus pallidus (green), thalamus (blue), dentate nucleus (yellow), and pons (red).

News | Contrast Media | January 11, 2018
January 11, 2018 — There is no evidence that accumulation in the brain of the element gadolinium speeds cognitive dec
Male Triathletes May Be Putting Their Heart Health at Risk
News | Cardiac Imaging | January 09, 2018
Competitive male triathletes face a higher risk of a potentially harmful heart condition called myocardial fibrosis,...
Videos | RSNA 2017 | December 20, 2017
ITN and DAIC Editor Dave Fornell takes a tour of some of the most interesting new medical imaging technologies on the
Videos | Magnetic Resonance Imaging (MRI) | December 19, 2017
Emanuel Kanal, M.D., director of MRI services and professor of radiology and neuroradiology at the University of Pitt
The FDA issued new warnings on MRI gadolinium contrast agents. (GBCAs)

The FDA issued new warnings on MRI gadolinium contrast agents. 

Feature | Magnetic Resonance Imaging (MRI) | December 19, 2017
The U.S.
Brainlab Contrast Clearance Analysis Software Receives FDA 510(k) Clearance
Technology | Contrast Media | December 12, 2017
Brainlab announced U.S. Food and Drug Administration (FDA) clearance of its Contrast Clearance Analysis methodology,...
Sectra Offers Gadolinium Tracking Functionality in DoseTrack Software
Technology | Contrast Media | December 11, 2017
December 11, 2017 — Sectra recently announced the global introduction of gadolinium tracking in its dose monitoring s
Videos | Magnetic Resonance Imaging (MRI) | December 07, 2017
Max Wintermark, M.D., professor of radiology and chief of neuroradiology, Stanford Hospital and Clinics, discussed MR
Overlay Init